To the full analysis
Fortis Healthcare stock: growth
FORTIS.NSFortis Healthcare reported $970.18M in revenue for fiscal 2026, up 17.2% on the prior year, up 17.8% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
16.4%
per year from 2007 to 2026, per share 15.4%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2021 | since 2016 | since 2007 | |
|---|---|---|---|
| Revenue | 17.8% | 8.1% | 16.4% |
| Revenue per share | 17.8% | 6.4% | 15.4% |
| Earnings | no data | 49.7% | no data |
| Earnings per share | no data | 49.3% | no data |
| Free cash flow | 10.4% | no data | no data |
| Free cash flow per share | 10.4% | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2007 | $54.46M | −$10.43M | −$4.18M |
| 2008 | $53.9M | −$5.9M | −$11.83M |
| 2009 | $67.02M | $2.21M | −$9.91M |
| 2010 | $99.69M | $7.39M | −$97.01M |
| 2011 | $157.62M | $13.22M | −$46.28M |
| 2012 | $317.17M | $7.68M | −$29.59M |
| 2013 | $323.37M | $51.55M | $132.15M |
| 2014 | $371.15M | $13.02M | −$12.14M |
| 2015 | $421.53M | −$15.27M | −$23.31M |
| 2016 | $446.29M | $1.96M | −$5.14M |
| 2017 | $486.13M | $44.82M | $75.74M |
| 2018 | $484.76M | −$107.27M | $39.7M |
| 2019 | $475.04M | −$31.77M | −$27.81M |
| 2020 | $492.36M | $6.16M | $1.66M |
| 2021 | $428.36M | −$11.67M | $28.38M |
| 2022 | $607.72M | $59M | $69.08M |
| 2023 | $669.37M | $62.58M | $39.86M |
| 2024 | $733.11M | $63.65M | $16.75M |
| 2025 | $827.57M | $82.29M | $61.33M |
| 2026 | $970.18M | $110.73M | $46.63M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ₹94.0836)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 8 Nov 2026, previously Weak
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.